Munich Gene & Cell Therapy Stage

Munich Gene & Cell Therapy Stage

The greater Munich area is a hub of innovation and entrepreneurial spirit.  The city is a major center for business, engineering, research, and medicine exemplified by the presence of two research universities, a multitude of smaller colleges, headquarters of several multinational companies and world-class technology and science museums. These features are making it one of the leading centres in Germany for medical engineering and a hidden champion with innovative capabilities.

The metropolitan area of Munich has two elite universities: the Technical University of Munich and Ludwig Maximilians university, which are leaders in biotechnology and have a lot of ongoing projects to help bring immunotherapy into widespread clinical use against cancer and infectious diseases.

With its innovation and start-up centres, specializing in biotechnology, the location benefits from a strong collaboration between academic research and the biotech industry, while emphasizing on personalized medicine and immunotherapy.

The 3rd International Conference on Lymphocyte engineering is a great opportunity to showcase the latest advancements and breakthroughs in Cell and Gene therapy. Do not miss this opportunity and become part of the community.

New transregional Collaborative Research Center (CRC) – TRR-338 LETSIMMUN (which stands for Lymphocyte Engineering for Therapeutic Synthetic Immunity) – will be based in Munich and Würzburg. The team under this project comprises of leading researchers from The Technical University and Ludwig-Maximilians-University of Munich and the University of Würzburg.

The Coordinator of the Center is Professor Dirk Busch, ICLE Conference Co-Chair and Director at the Institute for Med. Microbiology, Immunology and Hygene, Technical University of Munich (TUM).

The Local Coordinator at LMU is Professor Tobias Feuchtinger, Head of the Department of Pediatric Hematology, Oncology, Hemostaseology and Stem Cell Transplantation at Dr. von Hauner Children’s Hospital (which is part of the LMU Medical Center). Professor Tobias Feuchtinger is also an esteem member of the ICLE faculty and will deliver a talk at the Conference.

The DFG Collaborative Research Centers are among the most important research funding programs in Germany. They support complex, interdisciplinary and long-term research initiatives. They aim at developing new concepts in the field of adoptive T-cell therapy. The team will investigate – among other questions – how genetically engineered lymphocytes might be used to fight infections, tumors or autoimmune diseases. The group wishes to help establish immunotherapies with modified lymphocytes as a medically safe and effective treatment for as many patients as possible.